Gastrointestinal Cancer

The presence or absence of lymph node involvement has long been recognized as a critically relevant prognostic factor in solid tumor oncology.

Dr. Emily Chan from Vanderbilt-Ingram Cancer Center Discusses the Adjuvant Colorectal NO147 Trial

Dr. Axel Grothey from the Mayo Clinic Discusses Novel Agents for Colorectal Cancer

Colorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.

Investigators are recommending that black women follow a 'prudent dietary pattern' in lieu of a more Western-style diet to prevent the development of colorectal adenomas.

Dr. Axel Grothey from the Mayo Clinic on Trastuzumab for Gastroesophageal Cancer

New results suggest that a high intake of both natural and synthetic folate is associated with a decreased likelihood of colorectal cancer.

A look at the benefits of the chemoimmunotherapy rituximab for CLL and a look at the treatments and advances made in treating metastatic CRC.

A late phase metastatic colorectal cancer trial was stopped after demonstrating a statistically significant improvement in OS.

Aflibercept added to FOLFIRI chemotherapy improved PFS and OS in previously treated patients with metastatic colorectal cancer.

The iFOBT test examines the stool for hidden blood, which could come from anywhere in the GI tract, and possibly indicates a colon tumor or precancerous growths known as polyps.

A greater number of lymph nodes are being screened in colon cancer but this has not led to more diagnoses of node-positive colon cancer.

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Three new genetic mutations have been identified in patients with Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC).

Adding oxaliplatin to 5-fluorouracil before and after surgery for the treatment of locally advanced rectal cancer is demonstrating significant benefit.

A panel voted 9-6 advising the FDA not to approve dapagliflozin, a diabetes drug that forces the body to dump sugar.

The field of immunotherapy is brimming with questions that researchers are working to answer, and many of those efforts were on display at the ASCO annual meeting.

Almost 1 in 3 adults in the United States do not get screened regularly.

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST

A recent study showed that a patient-navigation-based intervention may help increase the rate of CRC screening in typically underserved groups, including low-income, ethnically diverse patients.

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.

A vast majority of Medicare patients with cancer are receiving appropriate surgical care that is in line with current treatment guidelines.

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Investigators in a large cohort study reported that heavy alcohol consumption, particularly beer, significantly increases the risk of gastric cancer.